In today’s briefing:
- Ohayo Japan | CPI Sends Stocks to New Highs
- [Blue Lotus Daily – TMT Update]:700 HK/BABA/Temu/Shein/PDD/CPNG/SE/AMZN/MELI/JD/1024 HK/2618 HK
- [Blue Lotus Daily]: BABA/TCOM/NIO/HTHT/ATAT
- Indian Contract Manufacturers: A Pair Trade Idea Between Gland Pharma and Syngene International
Ohayo Japan | CPI Sends Stocks to New Highs
- Overseas: SPX +0.5%; US Consumer prices +3.1% YoY; Oracle shares down -12% after Q2 miss
- Today: NKY Futs flat v cash. JPY 145.5; Renault initiates the sale of a 5% stake in Nissan
- Murakami takes 5.9% stake in Glosel; Macnica’s bid was too cheap. Expect a bump
[Blue Lotus Daily – TMT Update]:700 HK/BABA/Temu/Shein/PDD/CPNG/SE/AMZN/MELI/JD/1024 HK/2618 HK
- BABA/MELI/PDD/Shein/1519 HK: Cainiao launches charter flight route to Mexico (+/+/-/-/-/)
- 700 HK: Tencent gaming studio <Level Infinite> announced 4 new games at The Game Award 2023(+)
- BABA/Temu/Shein/CPNG/SE/AMZN/MELI: Alibaba plans to launch LLM AI-powered <1688> in South Korea(+/+/+/+/+/-/-)
[Blue Lotus Daily]: BABA/TCOM/NIO/HTHT/ATAT
- BABA/TCOM: China Tourism – Singapore and China to establish mutual 30-day visa exemption (+)
- NIO: NIO Auto to spin off its battery manufacturing business for financing (+)
- HTHT/ATAT: China Tourism Update – Chinese Embassies abroad temporarily reduce visa fees (+)
Indian Contract Manufacturers: A Pair Trade Idea Between Gland Pharma and Syngene International
- We are recommending to go long on Gland Pharma Ltd (GLAND IN) and short on Syngene International Ltd (SYNG IN).
- Gland Pharma, with its niche focus on generic injectables is expected to be outlier, while Syngene, with substantial exposure to early-stage biotech research will continue to have muted performance.
- Over the last six months, Gland Pharma shares rallied 83%, while Syngene International shares declined 5%. We expect the performance gap between the two companies will widen further.